Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Guzel Z Mukhametshina"'
Autor:
Irina V Kolyadina, Irina S Bulavina, Vladislav V Petkau, Natalia V Strakhova, Vera A Gorbunova, Elena I Kovalenko, Liudmila V Manziuk, Elena V Artamonova, Liudmila G Zhukova, Larisa V Bolotina, Inna P Gan'shina, Tatiana Iu Semiglazova, Aleksei G Manikhas, Natalia A Raevskaia, Ilia M Itkin, Svetlana V Khokhlova, Dmitrii V Filonenko, Viktor E Gol'dberg, Natalia O Popova, Dmitrii M Ponomarenko, Valentina E Shikina, Liubov I Vladimirova, Natalia M Tikhanovskaia, Elena V Karabina, Guzel Z Mukhametshina, Alfiia I Khasanova, Sufiia Z Safina, Mikhail V Shaidorov, Andrei E Orlov, Iuliia V Kostalanova, Natalia V Levchenko, Mikhail A Osipov, Tatiana V Karandeeva, Irina V Evstigneeva, Igor S Chernov, Dzheims Dzh Kolokolov, Anton Iu Povyshev, Alina S Shatokhina, Elena M Cherniakova, Oksana N Shkodenko, Evgeniia S Kuz'mina
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 17-24 (2019)
Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials
Externí odkaz:
https://doaj.org/article/5f21fe71ca7c49f6a857b2579dfadccd
Autor:
Igor V. Samoylenko, Lev V. Demidov, Fedor V. Moiseenko, Mikhail V. Dvorkin, Svetlana A. Demidova, Svetlana A. Protsenko, Daniil L. Stroyakovskiy, Vadim V. Kozlov, Svetlana V. Odintsova, Dmitry V. Kirtbaya, Denis A. Tantsyrev, Anastasia S. Mochalova, Rashida V. Orlova, Guzel Z. Mukhametshina, Natalia V. Fadeeva, Evgeny A. Fomin, Yana S. Chapko, Anna V. Tarasova, Nikolay B. Ermakov, Alexander K. Shemerovskiy, Vera A. Vaschenko, Valery M. Chistyakov, Arina V. Zinkina-Orikhan, Yulia N. Lin'kova, Fedor B. Kryukov, Irina V. Sorokina, Anna A. Siliutina
Publikováno v:
Современная онкология, Vol 25, Iss 3, Pp 313-324 (2023)
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination of PD-1 and CTLA-4 inhibitors a new standard of care for patients with metastatic melanoma (MM). A significant limitation of the widespread
Externí odkaz:
https://doaj.org/article/8e208259878448f396ff73ddc1f745f9
Autor:
Elena I. Kovalenko, Elena V. Artamonova, Elena V. Karabina, Irina I. Andreiashkina, Ekaterina A. Prokof’eva, Nataliia O. Popova, Elena A. Gaisina, Irina V. Evstigneeva, Mikhail V. Shaidorov, Larisa A. Zhiliaeva, Dmitrii M. Ponomarenko, Alfiia I. Khasanova, Guzel Z. Mukhametshina, Anton E. Koziakov, Liudmila V. Vorotilina, Anton Iu. Povyshev, Elena I. Simolina, Vasilii V. Marfutov, Dmitrii V. Kozlov, Irina R. Suslova, Valentina E. Shikina, Tatiana V. Karandeeva, Artem O. Shepel’, Liudmila V. Kramskaia, Denis A. Oskirko, Olga S. Frolova
Publikováno v:
Современная онкология, Vol 22, Iss 1, Pp 53-59 (2020)
The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of thi
Externí odkaz:
https://doaj.org/article/348c12ae10644482a51e5fd30b93fd11
Autor:
Vera A Gorbunova, Irina V Kolyadina, Elena I Kovalenko, Liudmila V Manziuk, Elena V Artamonova, Liudmila G Zhukova, Larisa V Bolotina, Tat'iana Iu Semiglazova, Aleksei G Manikhas, Natal'ia A Raevskaia, Il'ia M Itkin, Dmitrii V Filonenko, Larisa A Zhilyaeva, Viktor E Gol'dberg, Natal'ia O Popova, Dmitrii M Ponomarenko, Valentina E Shikina, Irina R Suslova, Olga V Romanchuk, Dmitrii V Kozlov, Ali-Dzarakhmat S Rzaev, Vasilii V Marfutov, Irina I Andreiashkina, Liubov' I Vladimirova, Irina S Mitashok, Natal'ia M Tikhanovskaia, Elena V Karabina, Guzel' Z Mukhametshina, Al'fiia I Khasanova, Sufiia Z Safina, Mikhail V Shaidorov, Dmitrii A Morozov, Elena P Prokof'eva, Liudmila V Kramskaia, Tat'iana V Karandeeva, Irina V Evstigneeva, Elena G Ovchinnikova, Tat'iana P Klement'eva, Olga V Khrupalo, Elena V Tiuvinova, Viktor M Sherstnev, Igor' S Chernov, Dzheims Dzh Kolokolov, Elena A Gaisina, Natal'ia V Levchenko, Viacheslav A Chubenko, Anton Iu Povyshev, Inna V Iudina, Liudmila V Vorotilina, Tat'iana V Andreeva, Garnik S Tumanian, Anton E Koziakov, Liudmila A Gil'mutdinova, Mikhail A Osipov, Alina S Shatokhina, Alena A Vazhenina, Angelina S Chichkanova, Vladimir I Vladimirov, Aleksandr N Ivanov, Anna S Belokhvostova, Elena M Cherniakova, Elena A Tul'china, Svetlana A Maklashova, Oksana N Shkodenko, Iuliia V Kostalanova, Anna V Tarasova, Evgeniia S Kuz'mina
Publikováno v:
Современная онкология, Vol 21, Iss 1, Pp 12-23 (2019)
Aim. The aim of the study is to examine the efficacy and safety of eribulin in HER2-negative metastatic breast cancer (BC) in Russian clinical practice. Materials and methods. The analysis included 459 patients with advanced BC from 44 federal and mu
Externí odkaz:
https://doaj.org/article/fab8f79eb72a4ebeb4af3ca5e29be2e9
Autor:
Mikhail V Shaidorov, Elena I. Simolina, Elena V. Artamonova, Denis A. Oskirko, Irina R. Suslova, Ekaterina A. Prokof’eva, Liudmila V. Kramskaia, Dmitrii V. Kozlov, Anton Iu Povyshev, Elena A. Gaisina, Irina I. Andreiashkina, Olga S. Frolova, Elena I. Kovalenko, Liudmila V. Vorotilina, Elena Karabina, Larisa A. Zhiliaeva, Tat'iana V Karandeeva, Guzel' Z Mukhametshina, Dmitrii M Ponomarenko, Artem O. Shepel, Al'fiia I Khasanova, Vasilii V. Marfutov, Valentina E Shikina, Irina V. Evstigneeva, Nataliia O. Popova, Anton E. Koziakov
Publikováno v:
Современная онкология, Vol 22, Iss 1, Pp 53-59 (2020)
The article presents the experience of 19 Russian medical institutions on the use of eribulin in combination with trastuzumab in various treatment lines of metastatic HER2+ breast cancer in routine clinical practice. Aim. The main objective of this r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea255c31ce421f5e2548d0e28cb3b9df
https://modernonco.orscience.ru/1815-1434/article/viewFile/34173/22585
https://modernonco.orscience.ru/1815-1434/article/viewFile/34173/22585
Autor:
Mikhail A Osipov, Iuliia V Kostalanova, Elena Karabina, Vera A Gorbunova, Dmitrii M Ponomarenko, Evgeniia S Kuz'mina, Al'fiia I Khasanova, Elena M Cherniakova, Natalia V Strakhova, Tat'iana V Karandeeva, Natal'ia V Levchenko, Inna P. Ganshina, Guzel' Z Mukhametshina, S V Khokhlova, Mikhail V Shaidorov, Tat'iana Iu Semiglazova, Irina S Bulavina, Liubov' I Vladimirova, Elena V. Artamonova, Dzheims Dzh Kolokolov, Il'ia M Itkin, Alina S Shatokhina, Aleksei G Manikhas, Larisa Bolotina, Natal'ia A Raevskaia, Igor' S Chernov, Oksana N Shkodenko, Dmitrii V Filonenko, N. O. Popova, V E Goldberg, Natal'ia M Tikhanovskaia, Irina V. Kolyadina, Sufiia Z Safina, Andrei E Orlov, Liudmila V Manziuk, Valentina E Shikina, Liudmila G. Zhukova, Irina V. Evstigneeva, Anton Iu Povyshev, Elena I. Kovalenko, Vladislav V Petkau
Publikováno v:
Современная онкология, Vol 21, Iss 2, Pp 17-24 (2019)
Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa692b452669005256eba3db6f5422bd
https://doi.org/10.26442/18151434.2019.2.190395
https://doi.org/10.26442/18151434.2019.2.190395
Autor:
Natal'ia M Tikhanovskaia, Elena Karabina, Igor' S Chernov, Tat'iana V Karandeeva, Mikhail A Osipov, Irina V. Kolyadina, Ali-Dzarakhmat S Rzaev, Dmitrii V. Kozlov, Sufiia Z Safina, Vasilii V. Marfutov, Elena P Prokof'eva, Oksana N Shkodenko, Alena A Vazhenina, Tat'iana V Andreeva, Elena G. Ovchinnikova, Irina R. Suslova, Elena I. Kovalenko, Olga V Khrupalo, Tat'iana Iu Semiglazova, Liudmila V. Vorotilina, Irina I. Andreiashkina, Elena V. Artamonova, Anton Iu Povyshev, Angelina S Chichkanova, Olga V Romanchuk, Vera A Gorbunova, Liubov' I Vladimirova, Elena A. Gaisina, Garnik S Tumanian, Iuliia V Kostalanova, Liudmila A Gil'mutdinova, Irina S Mitashok, Liudmila V Manziuk, Dmitrii M Ponomarenko, Evgeniia S Kuz'mina, Al'fiia I Khasanova, Guzel' Z Mukhametshina, Vladimir I. Vladimirov, Dmitrii A Morozov, Liudmila V. Kramskaia, Mikhail V Shaidorov, V E Goldberg, Inna V Iudina, Valentina E Shikina, Liudmila G. Zhukova, N. O. Popova, Irina V. Evstigneeva, Anton E. Koziakov, Elena A Tul'china, Elena V Tiuvinova, Il'ia M Itkin, Alina S Shatokhina, Aleksei G Manikhas, Dzheims Dzh Kolokolov, Anna S Belokhvostova, Natal'ia V Levchenko, Svetlana A Maklashova, Aleksandr N Ivanov, Larisa Bolotina, Anna V Tarasova, Dmitrii V Filonenko, Viacheslav A. Chubenko, Natal'ia A Raevskaia, Viktor M Sherstnev, Elena M Cherniakova, Tat'iana P Klement'eva, Larisa A Zhilyaeva
Publikováno v:
Современная онкология, Vol 21, Iss 1, Pp 12-23 (2019)
Aim. The aim of the study is to examine the efficacy and safety of eribulin in HER2-negative metastatic breast cancer (BC) in Russian clinical practice. Materials and methods. The analysis included 459 patients with advanced BC from 44 federal and mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a6a2dd4170f83bf2d09813743b639af
https://doi.org/10.26442/18151434.2019.1.190250
https://doi.org/10.26442/18151434.2019.1.190250
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c1c210914756da50d9c8f367b45ec1d
https://pubmed.ncbi.nlm.nih.gov/33387727
https://pubmed.ncbi.nlm.nih.gov/33387727
Autor:
Konstantin G. Shelepen, Anastasia N. Paltusova, Fedor Kryukov, Sergey M. Alexeev, Mariya S. Shustova, Sergey A. Kulik, Kirti Srivastava, Chiradoni Thugappa Satheesh, Olga Burdaeva, Guzel Z. Mukhametshina, Andrey V. Khorinko, Roman Ivanov, Mummaneni Vikranth
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e583dc70946efde96993e08fa512bc31
https://doi.org/10.1186/s12885-020-07247-9
https://doi.org/10.1186/s12885-020-07247-9
Autor:
Sergey M. Alexeev, Andrey V. Khorinko, Guzel Z. Mukhametshina, Konstantin G. Shelepen, Olga N. Burdaeva, Sergey A. Kulik, Chiradoni Thugappa Satheesh, Kirti Srivastava, Mummaneni Vikranth, Fedor Kryukov, Anastasia N. Paltusova, Mariya S. Shustova, Roman A. Ivanov
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clin
Externí odkaz:
https://doaj.org/article/91e85db418314c6180848ec4b818e417